Skip to main content
. 2019 Mar 27;63(4):e02291-18. doi: 10.1128/AAC.02291-18

FIG 4.

FIG 4

Binding and activity of CF-301. (A) Effects of serum and medium pretreatments on CF-301 binding to S. aureus MW2 determined by differential interference contrast (DIC) and fluorescence microscopy. Exposures of 3 ms (human, rabbit, and mouse plus HSA samples) and 3 s (rat, mouse, and caMHB samples) were used to visualize CF-301RHOD. MIC values for each condition are indicated (micrograms per milliliter). (B) Effect of HSA on CF-301 binding to S. aureus ATCC 700699 determined by deconvolution microscopy. Maximum-intensity projections are shown. CF-301RHOD, red; DAPI, blue (scale bar, 2 μm). (C) Effect of CF-301 on HuLYZ binding to S. aureus ATCC 700699 determined by deconvolution microscopy. Maximum-intensity projections are shown. HuLYZAF, green; DAPI, blue (scale bar, 4 μm). (D) Bactericidal activity of CF-301 in human serum and caMHB determined by TEM. CF-301 was tested at 10×, 1×, and 0.1× MIC levels for each environment. Direct magnification values: control, ×13,000; 10× MIC, ×2,600; 1× and 0.1× MIC, ×6,600. Scale bars, 1 μm.